A5062564734- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Colorectal Cancer Treatments and Studies
- PARP inhibition in cancer therapy
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis C virus research
- Nutrition and Health in Aging
- Diet and metabolism studies
- Nutrition, Genetics, and Disease
- Cancer Immunotherapy and Biomarkers
- Hepatitis B Virus Studies
Abstract Purpose: To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-) paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer (mTNBC). Patients Methods: The single-arm CO40151 phase Ib study (NCT03800836), the signal-seeking cohort of IPATunity130 (NCT03337724), randomized III IPATunity170 trial (NCT04177108) enrolled patients with previously untreated mTNBC. Triplet comprised intravenous atezolizumab...
<div>AbstractPurpose:<p>To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-) paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer (mTNBC).</p>Patients Methods:<p>The single-arm CO40151 phase Ib study (NCT03800836), the signal-seeking cohort of IPATunity130 (NCT03337724), randomized III IPATunity170 trial (NCT04177108) enrolled patients with previously untreated mTNBC. Triplet...
<div>AbstractPurpose:<p>To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-) paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer (mTNBC).</p>Patients Methods:<p>The single-arm CO40151 phase Ib study (NCT03800836), the signal-seeking cohort of IPATunity130 (NCT03337724), randomized III IPATunity170 trial (NCT04177108) enrolled patients with previously untreated mTNBC. Triplet...